Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

Melbourne biotech PolyActiva says it hopes to be the next Cochlear by selling its eye drug dispensing system to millions ...

Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ...

It's as if she's squinting through a smoke-filled room. But it's Charisse Brown's eye condition, glaucoma, that diminishes her vision. Brown, 38, has worked all her adult life, with a personal policy ...

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

As millions of Americans reach their 40s and 50s, many begin to experience the frustrating effects of presbyopia—the gradual ...

This week saw almost $65 million go to Aussie startups, including a last minute $40 million for PolyActiva which has been ...

Analysts have set 12-month price targets for Ocular Therapeutix, revealing an average target of $15.71, a high estimate of ...

Since launching in late 2023, the NRF has backed companies, including $32 million for Harrison.ai, $ 13 million for Quantum Brilliance, and $25 million for Myriota. Despite that, the PolyActiva deal ...